Abstract
One aspect of the recently published Nuffield Council on Bioethics’ report on Medical Profiling and Online Medicine centred on the development of direct-toconsumer (DTC) personal genomic services, and is the focus of Hood’s commentary in this issue of GSP. We have been prompted to make a number of comments in response to this piece (rather than to the report in its entirety). We would first like to state clearly that the work of the Nuffield group is welcomed and its report is a very useful contribution to ongoing discussions amongst academics, policy makers, and public interest groups about developments in the personalisation and online provision of various healthcare products and services.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
